Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.35 |
| ▸ | RAF1 | P04049 | 3/20 | 0.35 |
| ▸ | BRAF | P15056 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19783612 | 0.89 | PDE4A (0.33) | KMT2ANTRK1RAF1BRAF | |
| SCHEMBL19784138 | 0.89 | NTRK1 (0.36) | BTKMEN1KMT2ANTRK1 | |
| SCHEMBL19784204 | 0.89 | KDM4E (0.36) | KMT2ANTRK1 | |
| SCHEMBL21220084 | 0.88 | NTRK1 (0.36) | BTKMEN1KMT2ANTRK1 | |
| SCHEMBL19784203 | 0.88 | KMT2A (0.37) | MAPK8KMT2ANTRK1 | |
| SCHEMBL19784195 | 0.87 | MEN1 (0.39) | BTKMAPK8MEN1GAAKMT2A | |
| SCHEMBL21238304 | 0.87 | MEN1 (0.39) | BTKMAPK8MEN1GAAKMT2A | |
| SCHEMBL19783962 | 0.87 | NTRK1 (0.36) | MEN1KMT2ANTRK1 | |
| SCHEMBL19784127 | 0.87 | PDE4A (0.35) | NTRK1ALK | |
| SCHEMBL19784130 | 0.86 | IMPDH2 (0.40) | BTKMAPK8MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481823-B1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | US | disclosed |
| WO-2018011017-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | GLS, TNNI3, AADAC | BTK 3556/4885MAPK8 1132/4885MEN1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.